These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. Theunissen EL; Hutten NRPW; Mason NL; Toennes SW; Kuypers KPC; Ramaekers JG Cannabis Cannabinoid Res; 2019; 4(1):51-61. PubMed ID: 31363493 [No Abstract] [Full Text] [Related]
4. Novel halogenated synthetic cannabinoids impair sensorimotor functions in mice. Bilel S; Tirri M; Arfè R; Ossato A; Trapella C; Serpelloni G; Neri M; Fattore L; Marti M Neurotoxicology; 2020 Jan; 76():17-32. PubMed ID: 31610187 [TBL] [Abstract][Full Text] [Related]
5. Excretion of metabolites of the synthetic cannabinoid JWH-018 in urine after controlled inhalation. Toennes SW; Geraths A; Pogoda W; Paulke A; Wunder C; Theunissen EL; Ramaekers JG J Pharm Biomed Anal; 2018 Feb; 150():162-168. PubMed ID: 29245085 [TBL] [Abstract][Full Text] [Related]
6. Stimulation of in vivo dopamine transmission and intravenous self-administration in rats and mice by JWH-018, a Spice cannabinoid. De Luca MA; Bimpisidis Z; Melis M; Marti M; Caboni P; Valentini V; Margiani G; Pintori N; Polis I; Marsicano G; Parsons LH; Di Chiara G Neuropharmacology; 2015 Dec; 99():705-14. PubMed ID: 26327678 [TBL] [Abstract][Full Text] [Related]
7. Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. Theunissen EL; Reckweg JT; Hutten NRPW; Kuypers KPC; Toennes SW; Neukamm MA; Halter S; Ramaekers JG Psychopharmacology (Berl); 2022 May; 239(5):1251-1261. PubMed ID: 33501595 [TBL] [Abstract][Full Text] [Related]
8. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Every-Palmer S Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162 [TBL] [Abstract][Full Text] [Related]
9. Interactions between opioids and cannabinoids: Economic demand for opioid/cannabinoid mixtures. Maguire DR; France CP Drug Alcohol Depend; 2020 Jul; 212():108043. PubMed ID: 32497977 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation. Toennes SW; Geraths A; Pogoda W; Paulke A; Wunder C; Theunissen EL; Ramaekers JG Drug Test Anal; 2018 Apr; 10(4):644-650. PubMed ID: 28967189 [TBL] [Abstract][Full Text] [Related]
11. Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates. Cooper ZD; Evans SM; Foltin RW Exp Clin Psychopharmacol; 2021 Apr; 29(2):137-146. PubMed ID: 34043398 [TBL] [Abstract][Full Text] [Related]
12. Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. Cooper ZD; Poklis JL; Liu F Neuropharmacology; 2018 May; 134(Pt A):92-100. PubMed ID: 29146503 [TBL] [Abstract][Full Text] [Related]
13. Synthetic cannabinoid JWH-018 and its halogenated derivatives JWH-018-Cl and JWH-018-Br impair Novel Object Recognition in mice: Behavioral, electrophysiological and neurochemical evidence. Barbieri M; Ossato A; Canazza I; Trapella C; Borelli AC; Beggiato S; Rimondo C; Serpelloni G; Ferraro L; Marti M Neuropharmacology; 2016 Oct; 109():254-269. PubMed ID: 27346209 [TBL] [Abstract][Full Text] [Related]
14. Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy. Brents LK; Zimmerman SM; Saffell AR; Prather PL; Fantegrossi WE J Pharmacol Exp Ther; 2013 Sep; 346(3):350-61. PubMed ID: 23801678 [TBL] [Abstract][Full Text] [Related]
16. Novel halogenated derivates of JWH-018: Behavioral and binding studies in mice. Vigolo A; Ossato A; Trapella C; Vincenzi F; Rimondo C; Seri C; Varani K; Serpelloni G; Marti M Neuropharmacology; 2015 Aug; 95():68-82. PubMed ID: 25769232 [TBL] [Abstract][Full Text] [Related]
17. Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Tai S; Hyatt WS; Gu C; Franks LN; Vasiljevik T; Brents LK; Prather PL; Fantegrossi WE Pharmacol Res; 2015 Dec; 102():22-32. PubMed ID: 26361728 [TBL] [Abstract][Full Text] [Related]
18. What are the psychological effects of using synthetic cannabinoids? A systematic review. Akram H; Mokrysz C; Curran HV J Psychopharmacol; 2019 Mar; 33(3):271-283. PubMed ID: 30789300 [TBL] [Abstract][Full Text] [Related]
19. Acute Pharmacological Effects and Oral Fluid Concentrations of the Synthetic Cannabinoids JWH-122 and JWH-210 in Humans After Self-Administration: An Observational Study. Martínez L; La Maida N; Papaseit E; Pérez-Mañá C; Poyatos L; Pellegrini M; Pichini S; Ventura M; Galindo L; Busardò FP; Farré M Front Pharmacol; 2021; 12():705643. PubMed ID: 34489699 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. Toennes SW; Geraths A; Pogoda W; Paulke A; Wunder C; Theunissen EL; Ramaekers JG J Pharm Biomed Anal; 2017 Jun; 140():215-222. PubMed ID: 28365515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]